Incyte enters into potential $491M collaboration with Chinese biopharm firm
December 17, 2018 at 09:44 AM EST
Incycte will receive $40M upfront and potential milestone payments worth up to $351M from Innovent Biologics, which gets licensing rights to three new drug candidates.
